A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Study Summary

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Conditions

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Interventions / Drugs

Sacituzumab tirumotecan Bevacizumab H1 receptor antagonist H2 receptor antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid mouthwash (dexamethasone or equivalent)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment770 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.206363+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.